Peptide-Based siRNA Nanocomplexes Targeting Hepatic Stellate Cells.

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Hepatology

Background:

• Liver fibrosis results from excessive extracellular matrix accumulation due to chronic liver injury.
• Activated hepatic stellate cells (HSCs) are primary drivers of ECM deposition in liver fibrosis.
• Insulin-like growth factor 2 receptor (IGF2R) is overexpressed on activated HSCs, serving as a specific marker.

Purpose of the Study:

• To develop a targeted siRNA delivery system for activated HSCs to treat liver fibrosis.
• To overcome the immunogenicity concerns associated with protein-based siRNA delivery systems.
• To enhance the specificity and efficacy of siRNA delivery to HSCs using an IGF2R-specific peptide.

Main Methods:

• Modification of a peptide-based siRNA nanocomplex with an IGF2R-specific peptide, incorporating a short spacer and glutamate residues.
• Evaluation of the HSC specificity of the modified nanocomplex (IGF2R-3GK6E peptide) compared to an unmodified control.
• Assessment of the nanocomplex's potential for delivering Pcbp2 siRNA to activated HSCs.

Main Results:

• The IGF2R-3GK6E peptide-modified siRNA nanocomplex demonstrated enhanced specificity for activated HSCs.
• The modified nanocomplex showed improved binding affinity and uptake by activated HSCs.
• The peptide-based nanocomplex serves as a viable platform for targeted Pcbp2 siRNA delivery.

Conclusions:

• The IGF2R-specific peptide modification significantly improves the targeting of siRNA nanocomplexes to activated HSCs.
• This novel peptide-based nanocomplex represents a promising strategy for liver fibrosis therapy.
• Targeted delivery of Pcbp2 siRNA using this platform holds potential for treating liver fibrosis.